Naumovski L - Search Results

1

Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.

Naumovski L, Junutula JR. Naumovski L, et al. Curr Opin Mol Ther. 2010 Apr;12(2):248-57. Curr Opin Mol Ther. 2010. PMID: 20373269

2

Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy.

Johnson L, Huseni M, Smyczek T, Lima A, Yeung S, Cheng JH, Molina R, Kan D, De Mazière A, Klumperman J, Kasman I, Zhang Y, Dennis MS, Eastham-Anderson J, Jubb AM, Hwang O, Desai R, Schmidt M, Nannini MA, Barck KH, Carano RA, Forrest WF, Song Q, Chen DS, Naumovski L, Singh M, Ye W, Hegde PS. Johnson L, et al. Among authors: naumovski l. J Clin Invest. 2013 Sep;123(9):3997-4009. doi: 10.1172/JCI67892. Epub 2013 Aug 15. J Clin Invest. 2013. PMID: 23945239 Free PMC article.

3

Tumor localization and antitumor efficacy of novel sapphyrin compounds.

Naumovski L, Sirisawad M, Lecane P, Chen J, Ramos J, Wang Z, Cortez C, Magda D, Thiemann P, Boswell G, Miles D, Cho DG, Sessler JL, Miller R. Naumovski L, et al. Mol Cancer Ther. 2006 Nov;5(11):2798-805. doi: 10.1158/1535-7163.MCT-06-0246. Mol Cancer Ther. 2006. PMID: 17121926

4

Sapphyrins induce apoptosis in hematopoietic tumor-derived cell lines and show in vivo antitumor activity.

Naumovski L, Ramos J, Sirisawad M, Chen J, Thiemann P, Lecane P, Magda D, Wang Z, Cortez C, Boswell G, Gyu Cho D, Sessler J, Miller R. Naumovski L, et al. Mol Cancer Ther. 2005 Jun;4(6):968-76. doi: 10.1158/1535-7163.MCT-04-0339. Mol Cancer Ther. 2005. PMID: 15956254

5

Motexafin gadolinium-induced cell death correlates with heme oxygenase-1 expression and inhibition of P450 reductase-dependent activities.

Evans JP, Xu F, Sirisawad M, Miller R, Naumovski L, de Montellano PR. Evans JP, et al. Among authors: naumovski l. Mol Pharmacol. 2007 Jan;71(1):193-200. doi: 10.1124/mol.106.028407. Epub 2006 Oct 3. Mol Pharmacol. 2007. PMID: 17018578

6

First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.

Strickler JH, Weekes CD, Nemunaitis J, Ramanathan RK, Heist RS, Morgensztern D, Angevin E, Bauer TM, Yue H, Motwani M, Parikh A, Reilly EB, Afar D, Naumovski L, Kelly K. Strickler JH, et al. Among authors: naumovski l. J Clin Oncol. 2018 Nov 20;36(33):3298-3306. doi: 10.1200/JCO.2018.78.7697. Epub 2018 Oct 4. J Clin Oncol. 2018. PMID: 30285518 Free article. Clinical Trial.

7

Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification.

Wang J, Goetsch L, Tucker L, Zhang Q, Gonzalez A, Vaidya KS, Oleksijew A, Boghaert E, Song M, Sokolova I, Pestova E, Anderson M, Pappano WN, Ansell P, Bhathena A, Naumovski L, Corvaia N, Reilly EB. Wang J, et al. Among authors: naumovski l. BMC Cancer. 2016 Feb 16;16:105. doi: 10.1186/s12885-016-2138-z. BMC Cancer. 2016. PMID: 26879245 Free PMC article.

8

Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors.

Strickler JH, LoRusso P, Salgia R, Kang YK, Yen CJ, Lin CC, Ansell P, Motwani M, Wong S, Yue H, Wang L, Reilly E, Afar D, Naumovski L, Ramanathan RK. Strickler JH, et al. Among authors: naumovski l. Mol Cancer Ther. 2020 May;19(5):1210-1217. doi: 10.1158/1535-7163.MCT-19-0529. Epub 2020 Mar 3. Mol Cancer Ther. 2020. PMID: 32127466 Clinical Trial.

9

ABT-165, a Dual Variable Domain Immunoglobulin (DVD-Ig) Targeting DLL4 and VEGF, Demonstrates Superior Efficacy and Favorable Safety Profiles in Preclinical Models.

Li Y, Hickson JA, Ambrosi DJ, Haasch DL, Foster-Duke KD, Eaton LJ, DiGiammarino EL, Panchal SC, Jiang F, Mudd SR, Zhang C, Akella SS, Gao W, Ralston SL, Naumovski L, Gu J, Morgan-Lappe SE. Li Y, et al. Among authors: naumovski l. Mol Cancer Ther. 2018 May;17(5):1039-1050. doi: 10.1158/1535-7163.MCT-17-0800. Epub 2018 Mar 28. Mol Cancer Ther. 2018. PMID: 29592882

10

Motexafin gadolinium modulates levels of phosphorylated Akt and synergizes with inhibitors of Akt phosphorylation.

Ramos J, Sirisawad M, Miller R, Naumovski L. Ramos J, et al. Among authors: naumovski l. Mol Cancer Ther. 2006 May;5(5):1176-82. doi: 10.1158/1535-7163.MCT-05-0280. Mol Cancer Ther. 2006. PMID: 16731749

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

76 results

Search Page

Filters